
Globus Medical (GMED) Stock Forecast & Price Target
Globus Medical (GMED) Analyst Ratings
Bulls say
Globus Medical is poised for growth, driven by faster-than-expected expansion in the spine market and solid performance in its Enabling Technologies segment, with Nevro sales projected to improve sequentially and contribute significantly to revenue. The company is expected to experience strong free cash flow and enhanced balance sheet flexibility, positioning it for organic growth and potential revenue guidance upside. Furthermore, as Globus Medical completes the integration of NuVasive and optimizes manufacturing processes, anticipated gross margin expansion should stabilize EBITDA margins around 34-35% in 2026, reinforcing the positive outlook for the company's financial performance.
Bears say
Globus Medical faces a notably negative outlook primarily due to anticipated slower growth in the spine market, which is crucial for its revenue generation, as well as potential disruptions stemming from recent mergers involving NuVasive and Nevro. The company's bear case scenario suggests an expectation of revenue growth declining to low single digits, alongside flat margins, indicating a challenging financial environment. Additionally, various risks, such as delayed product launches, increased competition in the musculoskeletal space, and unfavorable changes in reimbursement, further underscore the uncertainties surrounding the company's future financial performance.
This aggregate rating is based on analysts' research of Globus Medical and is not a guaranteed prediction by Public.com or investment advice.
Globus Medical (GMED) Analyst Forecast & Price Prediction
Start investing in Globus Medical (GMED)
Order type
Buy in
Order amount
Est. shares
0 shares